Home Overview Press Room Blog Publications For Students about us
Search

Biotech & Pharma : Displaying 11-20 of 2599


2016 Fear vs Hope: Gene Editing— Terrible turning point?by Pete ShanksDeccan ChronicleJanuary 1st, 2017As the tools for gene editing rapidly advance, we approach our best chance to prevent the rise of a modern, uncontrolled and dangerously ill-considered techno-eugenics.
Unexpected Risks Found In Replacing DNA To Prevent Inherited Disordersby Jill NeimarkNPRJanuary 1st, 2017Scientists are increasingly concerned that "3-person IVF" techniques may allow flawed mitochondria to resurface and threaten a child's health.
China’s $9 billion effort to beat the U.S. in genetic testing[cites CGS's Marcy Darnovsky]by Ylan Q. MuiWashington PostDecember 30th, 2016Chinese investors — both private and government-supported — are backing American start-ups and funding promising new companies at home.
UC Davis professor wants FDA to create firm guidelines for stem-cell treatments, put clinics on noticeby Claudia BuckSacramento BeeDecember 24th, 2016Now is the time for the U.S. Food and Drug Administration to finalize guidelines and send notices to clinics that are offering untested treatments.
Lawmakers try to fix a side effect of reducing drug and theft crimes: Not enough DNA samples for cold casesby Jazmine UlloaLos Angeles TimesDecember 22nd, 2016A California bill would expand the state's DNA database, raising serious concerns about privacy and disproportionately targeting blacks and Latinos.
‘Gene drive’ moratorium shot down at UN biodiversity meetingby Ewen CallawayNatureDecember 21st, 2016Environmental activists’ appeals for a freeze on gene-drive field trials, and on some lab research, are likely to resurface in the future.
Why tech offers better fertility benefits than other industries[cites CGS's Marcy Darnovsky]by Alison DeNiscoTech RepublicDecember 21st, 2016The benefits are part of the current talent war for engineers and other professionals. Tech workers should be cautious about using the procedures.
Four Steps Forward, One Leap Back on Global Governance of Synthetic Biologyby ETC GroupETC GroupDecember 19th, 2016196 countries meeting at the UN Convention on Biodiversity grappled with how synthetic biology and other risky technologies threaten biodiversity, local economies, and the rights of farmers and Indigenous Peoples.
Gene-editing firms form patent alliance against Editas, Broadby Max StendahlBoston Business JournalDecember 16th, 2016The announcement formalizes a legal coordination and cost-sharing arrangement among four biotech companies.
Biopolitical News of 2016by Pete Shanks, Leah Lowthorp & Marcy DarnovskyBiopolitical TimesDecember 13th, 2016We highlight 2016’s trends in and top news stories about human biotech developments.
Displaying 11-20 of 2599  
< Prev  Next >> 
« First Page Last Page » 
« Show Complete List » 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1122 University Ave, Suite 100, Berkeley, CA 94702 • • (p) 1.510.665.7760 • (F) 1.510.665.8760